Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Neurology
25 active people
168 grants
Recent Grants
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
2024
·
$822.1K
stroke rehabilitation,
spasticity treatment,
drug safety,
efficacy evaluation,
tolerability assessment
A Treatment for Neuropsychological and Memory Impairments Following Moderate to Severe Traumatic Brain Injury
2023
·
$3M
neuropsychology,
memory impairments,
traumatic brain injury,
treatment,
cognitive rehabilitation
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: An FDA Required Toxicology
2023
·
$2.2M
cognitive impairment,
vascular dementia,
alzheimer's disease,
mas receptor agonist,
toxicology
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
2023
·
$749.8K
neuroscience,
epilepsy,
clinical trial,
drug resistance,
inhibitory interneurons
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
2023
·
$597.6K
parkinson's disease,
dose escalation,
clinical trial,
neurodegenerative diseases
A Phase 1b/2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy
2023
·
$543.6K
clinical trials,
pharmacology,
safety,
efficacy,
dose escalation
A Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral Fxla Inhibitor Asundexian (Bay 2433334) for the Secondary Prevention of Ischemic
2023
·
$399.7K
clinical trials,
cardiovascular disease,
pharmacology,
ischemic events,
drug development
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is
2023
·
$341.3K
stroke prevention,
factor xa inhibitor,
efficacy and safety,
acute ischemic stroke
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson?s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and i
2023
·
$308.7K
parkinson's disease,
dyskinesia,
efficacy,
safety/tolerability
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
2023
·
$275.7K
alzheimer disease,
natural products,
dementia,
treatment,
combinations
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport?) in Comparison with Onabotulinumto
2023
·
$226.2K
clinical safety,
efficacy evaluation
Identifying Human Neuron IFN-y Dependent Anti-Toxoplasma Gondii Responses
2023
·
$191.9K
neurobiology,
immunology,
infectious disease,
cell biology,
neuroimmunology
Patient-Based Postmortem Fibroblast Banking for Translational Research
2023
·
$20K
medical research,
biobanking,
translational research,
postmortem studies,
fibroblast research
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
2022
·
$3.7M
phytoserm,
menopause,
brain metabolism,
cognition,
clinical trial
Nonlipogenic ABCA1 Inducers for ADRD
2022
·
$1.9M
alzheimer's disease,
cholesterol metabolism,
drug discovery,
neurodegeneration,
lipid transport
Neural Stem Cell Mechanisms of Resilience Across the Lifespan
2022
·
$1.1M
neural stem cells,
resilience,
lifespan,
mechanisms,
neuroscience
Therapeutic Targeting of 5HT1F Receptor-Mediated Mitochondrial Biogenesis To Address Parkinson?s Disease
2022
·
$499.9K
parkinson's disease,
therapeutic targeting,
5-ht1f receptor,
mitochondrial biogenesis,
neurodegenerative diseases
Deep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cells
2022
·
$499.8K
mitochondrial dysfunction,
autophagy,
neurodegenerative diseases,
stem cells,
cellular mechanisms
Abbott DBS Post-Market Study of Outcomes for Indications over Time
2022
·
$432.1K
neuroscience,
medical devices,
clinical outcomes,
healthcare technology
Applying Pathomics to Establish a Biosignature for Aggressive Skin Melanoma
2022
·
$423.4K
pathomics,
biosignature,
skin melanoma,
aggressive,
establish
People
Anita Koshy
Associate Professor
Bruce Coull
Vice Dean
Ealaf Al rabia
Associate Clinical Professor, Neurology - (Clinical Series Track)
Firas Kaddouh
Assistant Clinical Professor, Neurology - (Clinical Series Track)
Francesca Vitali
Assistant Research Professor
Gerson Hernandez
Senior Director
Alex Hishaw
Associate Professor
Holli Horak
Professor
Jim ORourke
Clinical Research Coordinator II
Katalin Scherer
Professor
David Labiner
Department Head
Hong Lei
Professor, Neurology - (Clinical Scholar Track)
Linda Restifo
Professor
Lalitha Madhavan
Associate Professor
Mandi Corenblum
Research Technologist II
Myrka Torres
Associate Clinical Professor, Neurology - (Clinical Series Track)
Adriana O'Dell
Medical Education Program Professional I
Rui Chang
Associate Professor
Sudeshna Bose
Clinical Associate Professor, (Clinical Series Track)
Scott Richards
Clinical Research Coordinator II
Shriya Kavathia
Clinical Research Coordinator I
Scott Sherman
Professor
Vijayan Ramachandran
Scientific Analyst II
Yanyun Liu
Research Technologist I
Kuixi Zhu
Research Specialist, Principal
Research expenses history
Funding support
14 funding agencies since 2020